HLA-E Antigens

Class I human histocompatibility (HLA) antigens encoded by genes at the E locus on chromosome 6. They bind a restricted subset of peptides derived from the leader peptides of other class I molecules. They primarily are involved with down-regulating cytolytic activity of NK CELLS and restricting non-canonical CD8-POSITIVE T LYMPHOCYTES.

Also Known As:

Networked: 10 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Douik, Hayet: 1 article (04/2016)
2.	Guemira, Fethi: 1 article (04/2016)
3.	Romdhane, Neila Attia: 1 article (04/2016)
4.	Jia, Tianjun: 1 article (04/2015)
5.	Tang, Yuhong: 1 article (04/2015)
6.	Wu, Zhencun: 1 article (04/2015)
7.	Zhou, Yan: 1 article (04/2015)
8.	Donado, A F: 1 article (11/2014)
9.	Gómez, N: 1 article (11/2014)
10.	Lozano, E: 1 article (11/2014)

Related Diseases

1.	Infections 01/15/2006 - "The present study shows that the HLA-E(G) genetic variant (the HLA-E*0103 allele) alone is significantly (P = .001) associated with a 4.0-fold decreased risk of human immunodeficiency virus 1 (HIV-1) infection in Zimbabwean women. " 08/01/2013 - "As compared with the homozygous HLA-E*0101/0101 group, the CMV infection rate in HLA-E*0103 group displays statistical significance (P = 0.0295). " 08/01/2013 - "The results showed that the homozygous HLA-E*0101/0101 accounted for 20.17%, the homozygous HLA-E*0103/0103 accounted for 27.73%; heterozygous HLA-E*0101/0103 accounted for 52.10%; in homozygous HLA-E*0101/0101 group, 15 cases were infected with CMV and the CMV infection rate was 62.50%; in homozygous HLA-E*0103/0103 group, 16 cases were infected with CMV and the CMV infection rate was 48.48%; in heterozygous HLA-E*0101/0103 group 20 cases were infected with CMV and the CMV infection rate was 32.25%. " 01/01/2013 - "The MHC genes for HLA-A, -B, -C and HLA-E antigens were upregulated in human brain microvascular endothelial cells, the endothelial-like cell line, ECV 304 and human foreskin fibroblasts upon JEV infection. "
2.	Graft vs Host Disease (Graft-Versus-Host Disease) 11/01/2014 - "HLA-E*0103/E*0103 genotype is associated with lower risk of graft-versus-host disease, decreased mortality, and greater disease-free survival after bone marrow transplantation. " 12/15/2006 - "Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation." 03/01/2012 - "We showed a lower frequency of acute graft-versus-host disease (grade II or more; p=0.02) and chronic graft-versus-host disease (extensive; p=0.04) in the patients with HLA-E*0103/0103 genotype compared to other genotypes of HLA-E. " 03/01/2012 - "Conclusively, our results suggest a protective role for HLA-E*0103/0103 genotype against acute graft-versus-host disease (grade II or more) and chronic graft-versus-host disease (extensive) as well as an association between this genotype and a better overall survival after HLA-E matched allogeneic hematopoietic stem cell transplantation."
3.	Neoplasms (Cancer) 01/01/2023 - "Combined, the LMP-1 GGDPHLPTL and HLA-E*0103/0103 variants efficiently inhibited NKG2A+ NK cells, thereby facilitating the in vitro spread of EBV-infected tumor cells. "
4.	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 04/01/2016 - "Are HLA-E*0103 alleles predictive markers for nasopharyngeal cancer risk?"
5.	Breast Neoplasms (Breast Cancer) 04/01/2015 - "HLA-E*0103/HLA-E*0103 genotype is probably susceptible genotype for breast cancer, while plasma sHLA-E level probably has no association with breast cancer susceptibility." 04/01/2015 - "While in breast cancer patients with HLA-E*0103/HLA-E*0103 genotype, plasma levels of sHLA-E were significantly elevated compared with those in healthy controls. " 04/01/2015 - "The HLA-E*0103/HLA-E*0103 genotype significantly increased the risk for breast cancer. " 04/01/2015 - "The frequencies of HLA-E*0103 allele and HLA-E*0103/HLA-E*0103 genotype showed a significant difference between healthy controls and patients with breast cancer. "

Related Drugs and Biologics

1.	HLA-G Antigens (HLA G)
2.	HLA-A Antigens (HLA-A)

Related Therapies and Procedures

1.	Hematopoietic Stem Cell Transplantation
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow)